Form 8-K Intra-Cellular Therapies For: Apr 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq falls as Alphabet set for record loss amid AI spending woes
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- Moderna stock rises on latest cancer vaccine data publication
Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 14c
April 28, 2016 8:42 AM EDTIntra-Cellular Therapies (NASDAQ: ITCI) reported Q1 EPS of ($0.64), $0.14 better than the analyst estimate of ($0.78).
For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.
... More


